Alzheimer's Disease Neuropsychiatric and BPSD Treatment Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing therapies for behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease. BPSD encompasses a range of neuropsychiatric symptoms including agitation, aggression, depression, apathy, anxiety, hallucinations, and delusions. These symptoms significantly impact patient quality of life and caregiver burden.

The global BPSD treatment market is experiencing significant growth, driven by:

• Increasing diagnosis of Alzheimer's disease and related dementias
• Limited approved treatment options for neuropsychiatric symptoms
• Growing recognition of BPSD as a core component of AD management
• Novel mechanisms targeting serotonin, sigma-1 receptors, and orexin pathways

Key Therapeutic Approaches

| Mechanism | Target Symptoms | Companies |
|-----------|-----------------|-----------|
| 5-HT2A inverse agonists | Psychosis, agitation | Acadia, Otsuka |
| Sigma-1 receptor agonists | Agitation, anxiety | Axsome |
| GLP-1 receptor agonists | Cognitive decline, apathy | Novo Nordisk |
| Dopamine modulators | Motivation, apathy | Neurocrine |
| Anti-amyloid with BPSD benefits | Overall BPSD | Biogen/Eisai |

Companies

Axsome Therapeutics

[Axsome Therapeutics](/companies/axsome-therapeutics) is developing AXS-060, a sigma-1 receptor agonist for Alzheimer's disease agitation. Sigma-1 receptor activation has demonstrated neuroprotective effects and modulation of neuroinflammation.

Overview

This category page covers biotechnology and pharmaceutical companies developing therapies for behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease. BPSD encompasses a range of neuropsychiatric symptoms including agitation, aggression, depression, apathy, anxiety, hallucinations, and delusions. These symptoms significantly impact patient quality of life and caregiver burden.

The global BPSD treatment market is experiencing significant growth, driven by:

• Increasing diagnosis of Alzheimer's disease and related dementias
• Limited approved treatment options for neuropsychiatric symptoms
• Growing recognition of BPSD as a core component of AD management
• Novel mechanisms targeting serotonin, sigma-1 receptors, and orexin pathways

Key Therapeutic Approaches

| Mechanism | Target Symptoms | Companies |
|-----------|-----------------|-----------|
| 5-HT2A inverse agonists | Psychosis, agitation | Acadia, Otsuka |
| Sigma-1 receptor agonists | Agitation, anxiety | Axsome |
| GLP-1 receptor agonists | Cognitive decline, apathy | Novo Nordisk |
| Dopamine modulators | Motivation, apathy | Neurocrine |
| Anti-amyloid with BPSD benefits | Overall BPSD | Biogen/Eisai |

Companies

Axsome Therapeutics

[Axsome Therapeutics](/companies/axsome-therapeutics) is developing AXS-060, a sigma-1 receptor agonist for Alzheimer's disease agitation. Sigma-1 receptor activation has demonstrated neuroprotective effects and modulation of neuroinflammation.

• Lead Program: AXS-060 (Phase 2/3) — Sigma-1 receptor agonist for agitation
• Pipeline: AXS-05 (NMDA antagonist + sigma-1 agonist) for depression with agitation
• Status: Received FDA Fast Track designation for AD agitation

Otsuka Pharmaceutical

[Otsuka Pharmaceutical](/companies/otsuka) is a Japanese pharmaceutical leader with significant CNS expertise, developing brexpiprazole (Rexulti) for Alzheimer's disease psychosis and agitation. Brexpiprazole has a unique pharmacology as a serotonin-dopamine activity modulator.

• Lead Program: Brexpiprazole for AD psychosis (Phase 3)
• Pipeline: AI-031 (anti-amyloid), OPC-64005 for PD
• Status: Commercial product in schizophrenia and depression

Biogen

[Biogen](/companies/biogen) focuses on disease-modifying therapies for Alzheimer's disease (Leqembi, Aduhelm). By reducing amyloid burden, these therapies may subsequently reduce BPSD symptoms associated with amyloid pathology.

• Approved: Leqembi (lecanemab) — anti-amyloid antibody
• Pipeline: Next-generation anti-amyloid and tau programs
• Status: Commercial stage with ongoing label expansions

Acadia Pharmaceuticals

[Acadia Pharmaceuticals](/companies/acadia-pharmaceuticals) is a leader in neuropsychiatric drug development with Nuplazid (pimavanserin) approved for Parkinson's disease psychosis. The company is developing pimavanserin for Alzheimer's disease psychosis.

• Approved: Nuplazid (pimavanserin) for PDP
• Pipeline: Pimavanserin Phase 3 for AD psychosis; ACP-171 (orexin-2 agonist) for PD
• Status: Phase 3 trials in AD psychosis

Biohaven Pharmaceutical

[Biohaven](/companies/biohaven), acquired by Pfizer in 2023, is developing Kv7 potassium channel modulators and TDP-43 targeting therapies for neurodegeneration. Their platform addresses neuronal hyperexcitability implicated in neuropsychiatric symptoms.

• Pipeline: Kv7.2/7.3 modulators; TDP-43 targeting (BHVN-3744)
• Focus: ALS, AD, and neurological disorders
• Status: Clinical and preclinical stages

Novo Nordisk

[Novo Nordisk](/companies/novo-nordisk) is a major pharmaceutical company with a dominant position in metabolic diseases. Their GLP-1 receptor agonists (Ozempic, Wegovy) are being investigated for neuroprotective effects in Alzheimer's and Parkinson's disease.

• Pipeline: Semaglutide in Phase 3 trials for AD (EVOKE, EVOKE+)
• Mechanism: GLP-1 receptor activation for neuroprotection, reduced neuroinflammation
• Status: Large-scale Phase 3 trials ongoing

Neurocrine Biosciences

[Neurocrine Biosciences](/companies/neurocrine-biosciences) focuses on neuropsychiatric and neurological disorders. Their expertise in dopamine and GPCR signaling positions them for BPSD therapies targeting apathy and motivational symptoms.

• Focus: CNS disorders including movement disorders and neuropsychiatric conditions
• Pipeline: Various early-stage CNS programs
• Status: Research and development

Market Landscape

| Company | Market Cap (2026) | Key BPSD Program | Stage |
|---------|-------------------|-------------------|-------|
| Acadia | ~$6B | Pimavanserin (AD psychosis) | Phase 3 |
| Axsome | ~$6B | AXS-060 (agitation) | Phase 2/3 |
| Otsuka | ~$20B | Brexpiprazole (AD psychosis) | Phase 3 |
| Biogen | ~$20B | Leqembi (BPSD benefit) | Approved |
| Novo Nordisk | ~$500B | Semaglutide (AD) | Phase 3 |
| Biohaven (Pfizer) | — | Kv7 modulators | Preclinical |

Pipeline Summary

gantt
title BPSD Treatment Development Timeline
dateFormat YYYY-MM
axisFormat %Y

section Axsome
AXS-060 Phase 2/3 :active, 2025-01, 2026-12
AXS-05 Phase 3 (MDD) :active, 2024-06, 2026-06

section Acadia
Pimavanserin AD Psych :active, 2024-01, 2027-06

section Otsuka
Brexpiprazole AD :active, 2024-06, 2027-12

section Novo Nordisk
Semaglutide EVOKE :active, 2021-06, 2026-06
Semaglutide EVOKE+ :active, 2021-06, 2027-12

Clinical Trials Overview

| Company | Drug | NCT Number | Indication | Phase |
|---------|------|-------------|------------|-------|
| Acadia | Pimavanserin | NCT04331301 | AD Psychosis | Phase 3 |
| Axsome | AXS-060 | NCT05431461 | AD Agitation | Phase 2/3 |
| Otsuka | Brexpiprazole | NCT03902240 | AD Agitation | Phase 3 |
| Novo Nordisk | Semaglutide | NCT04777409 | AD (EVOKE) | Phase 3 |
| Novo Nordisk | Semaglutide | NCT04777396 | AD (EVOKE+) | Phase 3 |

References